vorasidenib
servier
['vorasidenib']
also at plenary today: vorasidenib in idh1 or idh2 mut low grade gliomas pfs 27.7 months vs 11.1 for placebo #asco23 
Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition